Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
Status:
Completed
Trial end date:
2021-09-27
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of KHK7791 in combination with phosphate binders by comparing
changes in serum phosphorus levels between hemodialysis patients with hyperphosphatemia
receiving repeated administration of KHK7791 30 mg in combination with phosphate binders for
6 weeks and those receiving placebo in combination with phosphate binders.